Title | 11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Wu, L, Liu, J, Feng, X, Dong, J, Qin, W, Liu, Y, Wang, J, Lu, J, Chen, K, Wang, Y, Jia, J |
Journal | J Alzheimers Dis |
Volume | 61 |
Issue | 2 |
Pagination | 613-618 |
Date Published | 2018 |
ISSN | 1875-8908 |
Keywords | Adult, Biomarkers, Brain, Carbon Radioisotopes, Female, Frontotemporal Dementia, Heterozygote, Humans, Male, Middle Aged, Mutation, Parkinsonian Disorders, Pedigree, Positron-Emission Tomography, tau Proteins |
Abstract | Frontotemporal dementia with parkinsonism-linked to chromosome 17 (FTDP-17) is a rare autosomal dominant neurodegenerative disorder. Most patients with FTDP-17 carry the mutation in the microtubule-associated protein tau (MAPT) gene. Striatum is predominantly and early affected in FTDP-17. Five family members (two symptomatic patients and three presymptomatic mutation carriers) from a Chinese pedigree of FTDP-17 with N279K mutation in MAPT were enrolled. Parkinsonism was the initial symptom for symptomatic patients. 2b-carbomethoxy-3b-(4-trimethylstannylphenyl) tropane (11C-CFT) uptake was obviously affected in the putamen of two presymptomatic mutation carriers. Presymptomatic case 3, whose 11C-CFT uptake in the right putamen was normal at baseline, was still free of parkinsonism during follow-up. In conclusion, 11C-CFT-positron emission tomography could be a potential biomarker for the presymptomatic stage of FTDP-17 to predict the disease onset. |
DOI | 10.3233/JAD-170561 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 29226866 |